Ectopic Lymphoid-organ Development Occurs Through Interleukin 7-mediated Enhanced Survival of Lymphoid-tissue-inducer Cells
Overview
Authors
Affiliations
Development of Peyer's patches and lymph nodes requires the interaction between CD4+ CD3- IL-7Ralpha+ lymphoid-tissue inducer (LTi) and VCAM-1+ organizer cells. Here we showed that by promoting their survival, enhanced expression of interleukin-7 (IL-7) in transgenic mice resulted in accumulation of LTi cells. With increased IL-7 availability, de novo formation of VCAM-1+ Peyer's patch anlagen occurred along the entire fetal gut resulting in a 5-fold increase in Peyer's patch numbers. IL-7 overexpression also led to formation of multiple organized ectopic lymph nodes and cecal patches. After immunization, ectopic lymph nodes developed normal T cell-dependent B cell responses and germinal centers. Mice overexpressing IL-7 but lacking either RORgamma, a factor required for LTi cell generation, or lymphotoxin alpha1beta2 had neither Peyer's patches nor ectopic lymph nodes. Therefore, by controlling LTi cell numbers, IL-7 can regulate the formation of both normal and ectopic lymphoid organs.
Ruiz-Torres D, Bryan M, Hirayama S, Merkin R, Luciani E, Roberts T Oncoimmunology. 2025; 14(1):2466308.
PMID: 39963988 PMC: 11845054. DOI: 10.1080/2162402X.2025.2466308.
IL-33-activated ILC2s induce tertiary lymphoid structures in pancreatic cancer.
Amisaki M, Zebboudj A, Yano H, Zhang S, Payne G, Chandra A Nature. 2025; 638(8052):1076-1084.
PMID: 39814891 PMC: 11864983. DOI: 10.1038/s41586-024-08426-5.
Immune Cell Densities Predict Response to Immune Checkpoint-Blockade in Head and Neck Cancer.
Ruiz-Torres D, Bryan M, Hirayama S, Merkin R, Luciani E, Roberts T medRxiv. 2024; .
PMID: 39314968 PMC: 11419212. DOI: 10.1101/2024.09.10.24313432.
Tertiary lymphoid structures in diseases: immune mechanisms and therapeutic advances.
Zhao L, Jin S, Wang S, Zhang Z, Wang X, Chen Z Signal Transduct Target Ther. 2024; 9(1):225.
PMID: 39198425 PMC: 11358547. DOI: 10.1038/s41392-024-01947-5.
Xu Z, Wang Q, Zhang Y, Li X, Wang M, Zhang Y Front Oncol. 2024; 14:1383096.
PMID: 38846981 PMC: 11153738. DOI: 10.3389/fonc.2024.1383096.